194 related articles for article (PubMed ID: 34334557)
21. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
[TBL] [Abstract][Full Text] [Related]
22. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
[TBL] [Abstract][Full Text] [Related]
23. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
[TBL] [Abstract][Full Text] [Related]
24. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
25. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
[TBL] [Abstract][Full Text] [Related]
26. Contractility assessment of human iPSC-derived cardiomyocytes by using a motion vector system and measuring cell impedance.
Satsuka A; Hayashi S; Yanagida S; Ono A; Kanda Y
J Pharmacol Toxicol Methods; 2022; 118():107227. PubMed ID: 36243255
[TBL] [Abstract][Full Text] [Related]
27. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
28. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
Toxicol Sci; 2021 Aug; 183(1):227-239. PubMed ID: 34142159
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
Takasuna K; Kazusa K; Hayakawa T
Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
[TBL] [Abstract][Full Text] [Related]
32. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
[TBL] [Abstract][Full Text] [Related]
33. Integrating nonlinear analysis and machine learning for human induced pluripotent stem cell-based drug cardiotoxicity testing.
Kowalczewski A; Sakolish C; Hoang P; Liu X; Jacquir S; Rusyn I; Ma Z
J Tissue Eng Regen Med; 2022 Aug; 16(8):732-743. PubMed ID: 35621199
[TBL] [Abstract][Full Text] [Related]
34. The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectations.
Gintant G; Traebert M
Expert Opin Drug Discov; 2020 Jun; 15(6):719-729. PubMed ID: 32129680
[TBL] [Abstract][Full Text] [Related]
35. Bufalin-induced cardiotoxicity: new findings into mechanisms.
Li M; Wang XJ; Zhao Q; Wang JX; Xing HY; Zhang YZ; Zhang XX; Zhi YY; Li H; Ma J
Chin J Nat Med; 2020 Jul; 18(7):550-560. PubMed ID: 32616195
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of contractile functions of human iPS-derived cardiomyocytes using motion field imaging].
Yamaguchi M; Sakamoto K; Kurokawa J
Nihon Yakurigaku Zasshi; 2021; 156(4):214-219. PubMed ID: 34193698
[TBL] [Abstract][Full Text] [Related]
37. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
38. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.
Ahmad T; Yin P; Saffitz J; Pockros PJ; Lalezari J; Shiffman M; Freilich B; Zamparo J; Brown K; Dimitrova D; Kumar M; Manion D; Heath-Chiozzi M; Wolf R; Hughes E; Muir AJ; Hernandez AF
Hepatology; 2015 Aug; 62(2):409-16. PubMed ID: 25251156
[TBL] [Abstract][Full Text] [Related]
39. Does Enhanced Structural Maturity of hiPSC-Cardiomyocytes Better for the Detection of Drug-Induced Cardiotoxicity?
Van de Sande D; Ghasemi M; Watters T; Burton F; Pham L; Altrocchi C; Gallacher DJ; Lu H; Smith G
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189424
[TBL] [Abstract][Full Text] [Related]
40. Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues.
Xu H; Liu G; Gong J; Zhang Y; Gu S; Wan Z; Yang P; Nie Y; Wang Y; Huang ZP; Luo G; Chen Z; Zhang D; Cao N
Adv Sci (Weinh); 2022 Oct; 9(30):e2203388. PubMed ID: 36055796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
